Overview

* PolyPid ( PYPD ) reports Q3 net loss of $7.5 mln, down from $7.8 mln last year

* Company advances regulatory strategy with pre-NDA meeting scheduled for December

* PolyPid ( PYPD ) progresses in U.S. partnership talks post positive Phase 3 trial results

Outlook

* PolyPid ( PYPD ) plans NDA submission for D-PLEX₁₀₀ in early 2026

* Company advancing U.S. partnership discussions for D-PLEX₁₀₀

* PolyPid ( PYPD ) expects cash balance to fund operations into 2026

Result Drivers

* R&D - The increase in R&D expenses was primarily due to activities related to the completion of the SHIELD II Phase 3 trial and preparation for regulatory submissions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $0.37

Q3 Net $7.45

Income mln

Q3 $7.46

Operatin mln

g Income

Q3 $7.43

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for PolyPid Ltd ( PYPD ) is $13.00, about 71.1% above its November 11 closing price of $3.76

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)